Immune signatures of patients with advanced non-small-cell lung cancer for efficacy prediction after immunotherapy.

ABSTRACT:

Background

Programmed cell death protein 1 ligand 1 (PD-L1) expression alone may not be the optimal predictor of immunotherapy (IO) efficacy in advanced non-small cell lung cancer (NSCLC). Evaluation of circulating immune signatures using mass cytometry is a promising technique for predicting IO response and prognosis. The utility of circulating immune signatures for efficacy prediction after IO in advanced NSCLC remains to be elucidated.

Objectives

To assess the feasibility of circulating immune cells and cytokines in predicting tumor response to IO in advanced NSCLC.

Design

A prospective observational study.

Methods

To investigate dynamic changes in immune signatures, blood specimens were prospectively collected from patients with NSCLC at baseline and follow

SUBMITTER: Luo YH 

PROVIDER: S-EPMC11465298 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature